Comprehensive analysis of citrate effects during plateletpheresis in normal donors

Bolan, Charles D.; Greer, Sarah E.; Cecco, Stacey A.; Oblitas, Jaime; Rehak, Nadja N.; Leitman, Susan F.

doi:10.1046/j.1537-2995.2001.41091165.x

Cited by 99 publications

(141 citation statements)

References 19 publications

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…Our findings support data reported from most investigators [2][3][4]24] although predonation blood pressure is not widely accepted as risk factor for donor reactions [4]. As to citrate toxicity, the overall incidence found in our study (0.3%, 62/22,400) is similar to that observed in earlier studies [18,19,[28][29][30][31], and the higher rate of reactions in plateletpheresis donors when compared to plasmapheresis donors is probably due to the greater average volume of anticoagulant infused (322 vs. 147 ml, p < 0.001). Contrasting with previous reports [3,19] and in accordance with others studies [32], we found a very low rate (0.4%, 484/116,952) of venipuncture-related adverse events.…”

Section: Discussionsupporting

confidence: 92%

Frequency of Adverse Events during Blood and Apheresis Donations: A Single-Center Study

Franchini¹,

Gandini²,

Gandini³

et al. 2002

Transfus Med Hemother

View full text Add to dashboard Cite

Background: Blood and apheresis donations are widely considered safe, with a low incidence of adverse reactions and injuries. However, data reported in the medical literature on the prevalence of adverse events in donors and studies on the predictive risk factors for donor reactions are limited and contradictory. Material and Methods: From January 1998 to June 2001, we recorded at our transfusion center all adverse events occurring during 116,952 consecutive blood and apheresis donations (homologous and autologous whole blood donation, plasmapheresis and plateletpheresis). Results: 1,960 adverse events were reported (1.7% of all donations). With a frequency of 1.2%, vasovagal reactions, mostly of mild intensity, were the most commonly observed adverse event. The frequency of vasovagal reactions was significantly lower in autologous blood and apheresis donations than in homologous blood donations. Hematoma at the venipuncture site was the second most frequent adverse effect with a rate of 0.4%. A mild to moderate citraterelated toxicity was observed in 0.3% of apheresis donations. With an overall rate of 0.02%, severe adverse reactions (vasovagal, citrate-related and cardiopulmonary events) were very rare. No life-threatening adverse effect was reported, and no severe adverse event required hospitalization. Finally, we found that those donors who experienced adverse reactions were primarily first-time donors, were younger, and had a lower weight and predonation blood pressure than donors without reactions. Conclusions: Blood and apheresis donations are safe procedures with a low incidence of adverse reactions. Young age, first-time donation status, low weight and predonation blood pressure are predictive factors of donor reactions.

show abstract

Section: Discussionsupporting

confidence: 92%

Frequency of Adverse Events during Blood and Apheresis Donations: A Single-Center Study

Franchini¹,

Gandini²,

Gandini³

et al. 2002

Transfus Med Hemother

View full text Add to dashboard Cite

show abstract

“…The result of such a decrease in ionized calcium is that excitability of nerve membrane increase to the point where spontaneous depolarization can occur. 11 This produces signs and symptoms of citrate toxicity including perioral paresthesia, shivering, light headedness, twitching and tremors. In addition, some patients also experience nausea and vomiting.…”

Section: Resultsmentioning

confidence: 99%

Adverse donor reaction during and after plateletpheresis in a tertiary care centre

et al. 2017

View full text Add to dashboard Cite

Background: Plateletpheresis is the process of collecting platelets, a component of blood involved in blood clotting. The term specifically refers to the method of collecting the platelets, which is performed by a device used in blood donation that separate the platelets and return other portion of blood to the donor. Platelet transfusion can be a life-saving procedure in preventing and treating serious complications from bleeding and haemorrhage in patients having disorders manifesting as thrombocytopenia like in dengue patients, ITP, aplastic anemia, and patients undergoing chemotherapy for leukaemia. In this study, our goal was to retrospectively analyse the adverse reactions occurred during and immediately after plateletpheresis donations.Methods: From January 2015 to October 2016, a total of 66 plateletpheresis procedures were performed in department of transfusion medicine, GMC Jammu, Jammu and Kashmir, India which is a tertiary care hospital.Results: Total 66 procedures were performed during our study period from which, four (6.06%) adverse events were recorded. Out of these four, two (50%) donors suffered from tingling sensation, one (25%) suffered from nausea and vomiting and One (25%) from haematoma formation.Conclusions: In Conclusion, the result of our 22-month study survey document that apheresis procedures performed on cell separators are safe procedures with the low incidence of adverse reactions.

show abstract

“…[1][2][3] Several polymorphisms found to be associated with TAFI Ag levels have been already described, 1-4 but a recently performed segregation-linkage analysis indicates that the TAFI-linked quantitative trait loci is unlikely to be one of these already identified polymorphisms. 5 Recently, Brouwers et al reported the identification a new polymorphism, 1040C/T, in the coding region of the TAFI gene that …”

Section: Thr325ile Polymorphism Of the Tafi Gene Does Not Influence Tmentioning

confidence: 99%

“…3 The establishment of standard citrate administration rates for plateletpheresis has resulted in procedures that are generally well tolerated. 3,5 But during much longer LVL procedures, blood citrate accumulation may eventually outpace metabolism when citrate is administered at rates used during plateletpheresis, resulting in markedly decreased ionized calcium levels and severe donor symptoms. 6 There is no single standard method to reduce citrate toxicity during LVL.…”

mentioning

confidence: 99%

“…6,8,9 When dosed according to the citrate administration rate and infused with citrated blood immediately prior to entering the donor circulation, calcium infusions safely and reliably attenuate the decline that normally occurs in donor ionized calcium levels, since the fraction of total calcium present in ionized form exhibits a tight, linear relationship with blood citrate concentration. 5,6 The marked elevations in parathyroid hormone and decreases in potassium and phosphate that normally occur due to unopposed citrate administration during LVL are also ameliorated by calcium supplementation. 6 When citrate and calcium administration are linked in this fashion, we have noted no significant adverse effects related to calcium prophylaxis in more than 400 leukapheresis procedures of 12 to 25 liters processed, lasting 3 to 5 hours and performed at citrate infusion rates of 2.5 mg/kg/min and higher in children and adults.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Management of anticoagulation-associated toxicity during large-volume leukapheresis of peripheral blood stem cell donors

Bolan

Leitman

2002

Blood

Self Cite

View full text Add to dashboard Cite

Comprehensive analysis of citrate effects during plateletpheresis in normal donors

Abstract: Marked, progressive increases in serum citrate levels occur during plateletpheresis, accompanied by symptomatic decreases in iCa and iMg, with significantly increased renal excretion of calcium, magnesium, and citrate.

Cited by 99 publications

References 19 publications

Frequency of Adverse Events during Blood and Apheresis Donations: A Single-Center Study

Frequency of Adverse Events during Blood and Apheresis Donations: A Single-Center Study

Adverse donor reaction during and after plateletpheresis in a tertiary care centre

Management of anticoagulation-associated toxicity during large-volume leukapheresis of peripheral blood stem cell donors

Contact Info

Product

Resources

About